Αποτελέσματα Αναζήτησης
XYWAV ® (calcium, magnesium, potassium, and sodium oxybates) oral solution, 0.5 g/mL total salts (equivalent to 0.413 g/mL of oxybate) is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy, and for the treatment of idiopathic hypersomnia (IH) in adults.
XYWAV® (calcium, magnesium, potassium, and sodium oxybates) oral solution, 0.5 g/mL total salts (equivalent to 0.413 g/mL of oxybate) is indicated for the treatment of idiopathic hypersomnia (IH) in adults. WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.
XYWAV® (calcium, magnesium, potassium, and sodium oxybates) is the only FDA-approved Idiopathic Hypersomnia (IH) treatment studied across multiple symptoms for adults. See full Prescribing Information & BOXED Warning about serious side effects, CNS depression, and misuse and abuse.
“Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in...
Find frequently asked questions about Idiopathic Hypersomnia (IH) and XYWAV® (calcium, magnesium, potassium, and sodium oxybates) oral solution. See full Prescribing Information & BOXED Warning about serious side effects, CNS depression, and misuse and abuse.
Unlike stimulants that are taken during the day, XYWAV is taken at night to help treat multiple symptoms of Idiopathic Hypersomnia (IH), such as: Excessive daytime sleepiness. feeling very sleepy or tired during the day. Sleep inertia. severe grogginess or confusion when waking up. Cognitive impairment. “brain fog” Long sleep time.
Xywav (calcium, magnesium, potassium, and sodium oxybates), a CNS depressant distributed by Jazz Pharmaceuticals, was approved in August 2021 for treatment of Idiopathic Hypersomnia (IH), a condition characterized by recurrent excessive daytime sleepiness (EDS), typically with ‘sleep drunkenness and/or naps that are unrefreshing and long (greate...
